U.S. Markets closed

What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

Mike Benson
What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.